Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
about
Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing.Hippo pathway mediates resistance to cytotoxic drugs.Identification of genomic alterations in pancreatic cancer using array-based comparative genomic hybridization.Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancerAltering cancer transcriptomes using epigenomic inhibitorsPharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cellsGemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.The kinase inhibitor D11 induces caspase-mediated cell death in cancer cells resistant to chemotherapeutic treatment.An innovative hydrogel of gemcitabine-loaded lipid nanocapsules: when the drug is a key player of the nanomedicine structure.Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells.Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer.Involvement of Akt2/protein kinase B β (PKBβ) in the 8-Cl-cAMP-induced cancer cell growth inhibition.RLN2 Is a Positive Regulator of AKT-2-Induced Gene Expression Required for Osteosarcoma Cells Invasion and Chemoresistance.Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
P2860
Q34446744-47A208F7-0430-4B80-AA96-95CA257393C4Q34555337-67E355C6-7E17-4BBF-BCA0-7CCE843EA5C1Q34682133-BD5E7369-9A56-43D8-B8D8-C2F04CB7F983Q35131201-92147B9E-916D-4C0A-8847-E164BFE4E623Q35863203-760F012D-17EA-4F97-9F3E-0F566137D4DEQ36447737-AD391A49-BA48-4782-B027-9EE7B9B0F9DBQ37146688-616563DE-4591-4A8A-9629-748675298152Q38826790-A224F59C-CD35-41E4-BB28-EDB702AD6619Q39013388-E6A864F9-4C41-477F-8584-CC616360C26CQ39137614-E0488BE1-36CB-4A29-A31A-EA1C35EFA532Q39165812-329807BD-65DB-490B-87D7-86E7BFCFE28BQ39270158-9FA736F9-DB9B-4B22-BA6D-CA526A45BC37Q41682526-8BA65B52-BAF1-4E31-802D-A01795EC4915Q51474050-C054C512-CC92-4998-B6B6-89D47B4E4B3D
P2860
Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Inhibition of AKT2 enhances se ...... creatic ductal adenocarcinoma.
@ast
Inhibition of AKT2 enhances se ...... creatic ductal adenocarcinoma.
@en
type
label
Inhibition of AKT2 enhances se ...... creatic ductal adenocarcinoma.
@ast
Inhibition of AKT2 enhances se ...... creatic ductal adenocarcinoma.
@en
prefLabel
Inhibition of AKT2 enhances se ...... creatic ductal adenocarcinoma.
@ast
Inhibition of AKT2 enhances se ...... creatic ductal adenocarcinoma.
@en
P2093
P2860
P356
P1476
Inhibition of AKT2 enhances se ...... creatic ductal adenocarcinoma.
@en
P2093
Dianliang Zhang
Kejun Zhang
Xuelong Jiao
P2860
P304
P356
10.3390/IJMS13011186
P407
P577
2012-01-20T00:00:00Z